P2Y12, a New Platelet ADP Receptor, Target of Clopidogrel

Herbert, 1993, Clopidogrel, a novel antiplatelet and antithrombotic agent, Cardiovasc. Drug Rev., 11, 180, 10.1111/j.1527-3466.1993.tb00275.x

Savi, 2000, Pharmacology of ticlopidine and clopidogrel, Haematology, 85, 73

1996, Lancet, 348, 1329, 10.1016/S0140-6736(96)09457-3

Savi, 1994, Binding of [3H]-2-methylthio ADP to rat platelets—Effect of clopidogrel and ticlopidine, J. Pharmacol. Exp. Ther., 269, 2772

Mills, 1992, Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase, Arterioscler. Thromb., 12, 430, 10.1161/01.ATV.12.4.430

Savi, 2000, Identification and biological activity of the active metabolite of clopidogrel, Thromb. Haemost., 84, 891, 10.1055/s-0037-1614133

Savi, 1998, Role of P2Y1 purinoceptor in ADP-induced platelet activation, FEBS Lett., 422, 291, 10.1016/S0014-5793(98)00025-8

Savi, 1997, Characterization of P2x1 purinoreceptors on rat platelets: Effect of clopidogrel, Br. J. Haematol., 98, 880, 10.1046/j.1365-2141.1997.3133126.x

Zhang, 2001, ADP is the cognate ligand for orphan G-protein coupled receptor SP1999, JBC, 10.1074/jbc.M009718200

Hollopeter, 2001, Identification of the platelet ADP receptor targeted by antithrombotic drugs, Nature, 409, 202, 10.1038/35051599

Miloux, 1994, Rapid isolation of highly productive recombinant Chinese hamster ovary cell lines, Gene, 149, 341, 10.1016/0378-1119(94)90173-2

Urlaub, 1980, Isolation of Chinese hamster cell mutants deficient in dihydrofolate reductase activity, Proc. Nat. Acad. Sci. USA, 77, 4216, 10.1073/pnas.77.7.4216

Bennet, 1978, Methods in binding studies, 57

Jacobs, 1975, Estimation of hormone receptor affinity by competitive displacement of labeled ligand: Effect of concentration of receptor and of labeled ligand, Biochem. Biophys. Res. Commun., 66, 687, 10.1016/0006-291X(75)90564-1

Cheng, 1973, Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (IC50) of an enzymatic reaction, Biochem. Pharmacol., 22, 3099, 10.1016/0006-2952(73)90196-2

Munson, 1980, Ligand: A versatile computerized approach for characterization of ligand-binding systems, Anal. Biochem., 107, 220, 10.1016/0003-2697(80)90515-1

Meurs, 1980, Extraction of cyclic AMP for the determination in the competitive protein binding assay, Clin. Chim. Acta., 106, 91, 10.1016/0009-8981(80)90378-2

Wilson, 1998, Br. J. Pharmacol., 125, 1387, 10.1038/sj.bjp.0702238

Scatchard, 1949, The attractions of proteins for small molecules and ions, Ann. NY Acad. Sci., 51, 660, 10.1111/j.1749-6632.1949.tb27297.x

Macfarlane, 1983, 2-Methylthioadenosine[beta-32P]diphosphate. An agonist and radioligand for the receptor that inhibits the accumulation of cyclic AMP in intact blood platelets, J. Clin. Invest., 71, 420, 10.1172/JCI110786

Colman, 1990, Aggregin: A platelet ADP receptor that mediates activation, FASEB J., 4, 1425, 10.1096/fasebj.4.5.2407587

Nandanan, 2000, Synthesis, biological activity, and molecular modeling of ribose-modified deoxyadenosine bisphosphate analogues as P2Y(1) receptor ligands, J. Med. Chem., 43, 829, 10.1021/jm990249v

Savi, 1994, Evidence for the existence of two different ADP-binding sites on rat platelets, Thromb. Res., 76, 157, 10.1016/0049-3848(94)90186-4